Key Milestones2 | |
---|---|
Call for patient/clinician input open | December 23, 2021 |
Call for patient/clinician input closed | February 18, 2022 |
Clarification: - Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, Vision Loss Rehabilitation Canada | |
Submission received | January 31, 2022 |
Submission accepted | February 14, 2022 |
Review initiated | February 17, 2022 |
Draft Canada's Drug Agency review report(s) provided to sponsor for comment | May 04, 2022 |
Deadline for sponsors comments | May 13, 2022 |
Canada's Drug Agency review report(s) and responses to comments provided to sponsor | June 10, 2022 |
Expert committee meeting (initial) | June 22, 2022 |
Draft recommendation issued to sponsor | July 05, 2022 |
Draft recommendation posted for stakeholder feedback | July 14, 2022 |
End of feedback period | July 28, 2022 |
Final recommendation issued to sponsor and drug plans | August 12, 2022 |
Final recommendation posted | August 30, 2022 |
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | August 26, 2022 |
Canada's Drug Agency review report(s) posted | November 16, 2022 |
Informed by literature, the key objectives of this Environmental Scan are to:
Key Milestones2 | |
---|---|
Call for patient/clinician input open | 21-Sep-21 |
Call for patient/clinician input closed | 12-Nov-21 |
Clarification: - Patient input submission received from the Women's Health Coalition of Alberta Society | |
Submission received | 26-Oct-21 |
Submission accepted | 09-Nov-21 |
Review initiated | 10-Nov-21 |
Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 01-Feb-22 |
Deadline for sponsors comments | 10-Feb-22 |
Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 11-Mar-22 |
Expert committee meeting (initial) | 23-Mar-22 |
Draft recommendation issued to sponsor | 06-Apr-22 |
Draft recommendation posted for stakeholder feedback | 14-Apr-22 |
End of feedback period | 29-Apr-22 |
Final recommendation issued to sponsor and drug plans | 13-May-22 |
Final recommendation posted | 01-Jun-22 |
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 02-Jun-22 |
Canada's Drug Agency review report(s) posted | 11-Aug-22 |
There are not very many effective treatment options for Alzheimer disease and most of the options have side effects for many people, and temporarily reduce symptoms rather than delay disease progression. Effective treatments with minimal side effects that prevent and reduce the severity of Alzheimer disease are needed.
1. What is the clinical effectiveness of vitamin D supplementation for the prevention of falls and fractures in elderly patients residing in long-term care facilities? 2. What is the cost-effectiveness of vitamin D supplementation for the prevention of falls and fractures in elderly patients residing in long-term care facilities? 3. What are the evidence-based guidelines regarding vitamin D supplementation for the prevention of falls and fractures in elderly patients residing in long-term care facilities?